Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis

被引：0
|
作者：
R Zarate
J Rodríguez
E Bandres
A Patiño-Garcia
M Ponz-Sarvise
A Viudez
N Ramirez
N Bitarte
A Chopitea
J Gacía-Foncillas
机构：
[1] Laboratory of Pharmacogenomics,Division of Oncology
[2] CIMA,Department of Oncology
[3] Unit for the Research and Treatment of Gastrointestinal Malignancies,Department of Pediatrics
[4] Laboratory of Pediatrics,undefined
[5] University Clinic of Navarra,undefined
[6] Current address: Hospital Sant Pau i Santa Tecla,undefined
[7] Tarragona 43003,undefined
[8] Spain,undefined
来源：
British Journal of Cancer | 2010年 / 102卷
关键词：
capecitabine; irinotecan; oxaliplatin; metastatic colorectal cancer; GSTP1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：987 / 994
页数：7
相关论文
共 50 条
  • [1] Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis
    Zarate, R.
    Rodriguez, J.
    Bandres, E.
    Patino-Garcia, A.
    Ponz-Sarvise, M.
    Viudez, A.
    Ramirez, N.
    Bitarte, N.
    Chopitea, A.
    Gacia-Foncillas, J.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (06) : 987 - 994
  • [2] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Okagawa, Yutaka
    Murase, Kazuyuki
    Takada, Kohichi
    Kawano, Yutaka
    Iyama, Satoshi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Mizuguchi, Toru
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 587 - 594
  • [3] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer
    Yasushi Sato
    Hiroyuki Ohnuma
    Masahiro Hirakawa
    Minoru Takahashi
    Takahiro Osuga
    Yutaka Okagawa
    Kazuyuki Murase
    Kohichi Takada
    Yutaka Kawano
    Satoshi Iyama
    Tsuyoshi Hayashi
    Tsutomu Sato
    Koji Miyanishi
    Rishu Takimoto
    Masayoshi Kobune
    Kenji Okita
    Toru Mizuguchi
    Tomohisa Furuhata
    Koichi Hirata
    Junji Kato
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 75 : 587 - 594
  • [4] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [5] A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer
    Sato, Yasushi
    Ohnuma, Hiroyuki
    Hirakawa, Masahiro
    Takahashi, Minoru
    Osuga, Takahiro
    Takada, Kohichi
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Takimoto, Rishu
    Kobune, Masayoshi
    Okita, Kenji
    Furuhata, Tomohisa
    Hirata, Koichi
    Kato, Junji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
    Fornaro, Lorenzo
    Masi, G.
    Bursi, S.
    Loupakis, F.
    Vasile, E.
    Antonuzzo, A.
    Chiara, S.
    Pfanner, E.
    Di Paolo, A.
    Bocci, G.
    Del Tacca, M.
    Falcone, A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) : 965 - 969
  • [7] A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
    Lorenzo Fornaro
    G. Masi
    S. Bursi
    F. Loupakis
    E. Vasile
    A. Antonuzzo
    S. Chiara
    E. Pfanner
    A. Di Paolo
    G. Bocci
    M. Del Tacca
    A. Falcone
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 63 : 965 - 969
  • [8] Capecitabine and oxaliplatin in advanced colorectal cancer: A dose-finding study
    Zeuli, M
    Di Costanzo, F
    Sdrobolini, A
    Gasperoni, S
    Paoloni, FP
    Carpi, A
    Moscetti, L
    Cherubini, R
    Cognetti, F
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (12) : 1737 - 1741
  • [9] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
    Fonseca, P. J.
    Solis, P.
    Vieitez, J. M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Frunza, M.
    Uriol, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
  • [10] A triplet combination with capecitabine/oxaliplatin/irinotecan (XELOXIRI) plus cetuximab as first-line therapy for patients with metastatic colorectal cancer: a dose escalation study
    Sato, Yasushi
    Hirakawa, Masahiro
    Ohnuma, Hiroyuki
    Takahashi, Minoru
    Okamoto, Tetsuro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Furuhata, Tomohisa
    Takemasa, Ichiro
    Kato, Junji
    Takayama, Tetsuji
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1133 - 1139
12345